BR 790 - Shanghai Blueray Biopharma
Alternative Names: BR790 - Shanghai Blueray BiopharmaLatest Information Update: 03 Apr 2023
Price :
$50 *
At a glance
- Originator Shanghai Blueray Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action SH2 domain-containing protein tyrosine phosphatase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Mar 2023 BR 790 - Shanghai Blueray Biopharma is available for licensing as of 14 Mar 2023. http://www.brbiopharma.com/about/?144.html
- 14 Mar 2023 Preclinical trials in Solid tumours in China Prior to March 2023 (Shanghai Blueray Biopharma pipeline, March 2023)